Multidisciplinary Treatment of Early-Stage Non-Small Cell Lung Cancer

It is anticipated that there will be an increase in the detection of early-stage NSCLC with the increasing use of lung screening with LDCT. Treatment of early-stage NSCLC may involve surgery or SABR followed by additional surgery, chemotherapy, radiation therapy, or chemoradiation. Before a specific multidisciplinary treatment plan is recommended for an individual patient, multidisciplinary evaluation in tumor boards is often advised to ensure the patient receives the most appropriate treatment. The multidisciplinary team approach has been shown to improve outcomes in patients with lung cancer.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Discuss the need for multidisciplinary evaluation before treatment for patients with early-stage non-small cell lung cancer (NSCLC)
  • Describe multidisciplinary treatment for patients with medically operable early-stage NSCLC
  • Describe multidisciplinary treatment for patients with medically inoperable early-stage NSCLC
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Pfizer

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This educational activity is supported by an independent educational grant from Merck  & Co., Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
05/14/2021
Course expires: 
03/01/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Oncology Fellows Program: New Horizons in Quality Cancer Care

Thomas J. Dilling, MD, MS
Moffitt Cancer Center

Michael Lanuti, MD
Massachusetts General Hospital Cancer Center

Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care.  Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. 

Definitions  

NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships: 

Thomas J. Dilling, MD, MS
AstraZeneca Pharmaceuticals LP: Consulting Fee; Honoraria

Michael Lanuti, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee

Gregory A. Otterson, MD
AbbVie, Inc.: Grant/Research Support 
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Consulting Fee
Bristol-Myers Squibb Company: Grant/Research Support; Consulting Fee
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novocure: Consulting Fee
Pfizer Inc.: Grant/Research Support
Revolution Medicine: Grant/Research Support

NCCN Staff Disclosures

The NCCN Leadership listed below discloses no relevant financial relationships: 

Wui-Jin Koh, MD

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships: 

Miranda Hughes, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-046-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing